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ax-SPIRAL®: Cuban antileptospirosis vaccines for
umans: Clinical and ﬁeld assays and impact of the
accine on the disease after 11 years of application in
uba
. Martínez
Instituto de Medicina Tropical ¨Pedro Kourí¨, Ciudad
abana, Cuba
Background: In Cuba, leptospirosis has shown an ende-
oepidemic behavior, with an important increase in
orbility between 1991 and 1995, that is why these years
ave been considered epidemic. According to what had been
oreseen within the Leptospirosis Prevention and Control
rogram, a Russian vaccine was administered to persons at
isk of getting the disease since 1983. In 1991, import of
his vaccine was stopped and, in order to ﬁnd an alter-
ative solution to this health problem, it was decided
o start the development of a trivalent Cuban vaccine
ith autochthonous strains (Icteroahemorrahgiae, Canicola,
omona). The objective was to carry out the clinical evalua-
ion and to observe the impact of the Cuban vaccine against
uman leptospirosis in persons exposed to the risk of getting
his disease.
Methods: The ﬁrst studies conducted were controlled
linical assays to evaluate both reactogenicity and immuno-
enicity of the vaccine in different groups of volunteers.
ine hundred and ﬁfty-eight volunteers participated in the
tudies. To evaluate the vaccine efﬁcacy, a controlled, ran-
omized, double blind clinical assay was performed in Villa
lara province with 101 832 volunteers, who were followed
p for one year. Another studied was carried out in 101 137
ersons at risk in Holguin province with the same objective:
o evaluate the vaccine effectiveness.
Results: The clinical evaluation showed safety and low
eactogenicity. Immunogenicity was comparable to that of
ther bacterines. Efﬁcacy was of 78.1% (IC 95%: 58.2 to
8.3) and the RR of getting sick of vaccinated individuals,
ith regard to non-vaccinated ones, was 0.22. So, a protec-
ive effect of the vaccine administration was considered.
he vax-SPIRAL vaccine was registered in 1998 and included
ithin the Leptospirosis Prevention and Control Program.
ince the introduction of this vaccine, a marked decrease in
eptospirosis cases has been observed. It has been possible
o administered more than 8 million of doses and morbility
as been diminished to 84.1%.Conclusion: vax-SPIRAL is safe, little reactogenic vaccine
nd has turned out to be an effective measure for leptospiro-
is control in individuals exposed to the risk of getting sick.
oi:10.1016/j.ijid.2010.02.613
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mmunization with surface protein 2 (TcSP2) protects
ice from acute experimental Trypanosoma cruzi infec-
ion: A potential candidate for vaccine development
. Carabarin ∗, C. González, L. Baylon-Pacheco, J.L.
osales-Encina
CINVESTAV-IPN, México, Mexico
Background: Trypanosoma cruzi, the causative agent of
haga’s disease, is a protozoan parasite that affects mil-
ion of people in Latin America. TcSP2 is a surface protein
xpressed in amastigote, epimastigote and trypomastigote,
nd it is a promising molecule for a recombinant protein
accine against American Trypanosomiasis.
Methods: The TcSP2 gene was ampliﬁed by PCR using
s a template the plasmid pA83, cloned in the plasmid
RSETB and the his-tagged recombinant protein was puriﬁed
y nickel afﬁnity chromatography. Mice immunized (ip) with
he His-TcSP2 protein were infected (ip) with bloodstream
rypomastigotes H8, and parasitaemias and survival rates
ere monitored every other day. Serum samples from both
mmunized mice and challenged mice were assayed for anti-
cSP2 antibodies by ELISA (immunoglobulin isotype), and for
he measurement of cytokines by ﬂow cytometry. For histo-
ogical studies, sections of ﬁxed hearts were stained with
ematoxylin and eosin, and evaluated by light microscopy.
Results: Mice were bleed 15 days after the last immu-
ization and the anti-TcSP2 antibodies isotypes were deter-
ined. It was found a predominance of IgG1 < IgG2b < IgG2a
sotypes respectively. This isotype proﬁle indicates a non
olarized Th1/Th2 immune response. Immunized and unim-
unized mice were infected with blood trypomastigotes,
nd the parasitaemia proﬁles showed a 70% reduction in
arasite number in mice immunized with the recombi-
ant protein TcSP2 as compared with unimmunized animals
p < 0.05). Likewise, the surviving rate for both immunized
nd unimmunized animals was 100% and 25% respectively
p < 0.001). The Cytokine proﬁle at the end of the par-
sitaemia showed the presence of IL-10 and INF- in
mmunized and infected mice, and IL-4 in unimmunized
nd infected mice. These results indicate that a Th1-type
mmune response was polarized after parasite challenge.
inally, histopathological analysis of tissue sections from
nimmunized and infected mice showed an extensive inﬁl-
ration of inﬂammatory cells in heart as compared with the
bsence of cell inﬁltration in immunized and infected mice.
Conclusion: The ﬁndings of this study indicate that
mmunization with the TcSP2 recombinant protein induces
rotection against infection with Trypanosoma cruzi in the
ouse model. Therefore, TcSP2 recombinant protein may be
n excellent candidate for further vaccine development.
oi:10.1016/j.ijid.2010.02.614
